Trimetazidine dihydrochloride­ modified release tablet 35mg

CORADON MR 35 (Trimetazidine dihydrochloride­ modified release tablet 35mg)

Coradon MR-35 composed of Trimetazidine dihydrochloride 35 mg modified release. 
Trimetazidine is a drug for angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent.
  Indications
  Trimetazidine is indicated for use in angina pectoris
  Mechanism of action
Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. 
  Dosage
As prescribed by the physician.
  Pharmacology
  Absorption
Trimetazidine after oral administration and absorption from the digestive tract reaches the maximum concentration in the serum after about 5 hours from administration of the drug.
  Distribution
The volume of distribution is 4.8 l/kg.
  Excretion
Trimetazidine is eliminated mainly in the urine, in unchanged form. The average half-life is 7 hours, in patients over age 65 years it increases to 12 hours.
  Precautions
Inform your physician, if you are 
•  allergic to this medication or any of the other ingredients of this medication
•  are pregnant, planning to become pregnant, or breastfeeding
• are taking any other medications, including supplements, traditional medications and herbal remedies
• Suffering from kidney problems
• Suffering from Parkinson’s disease, tremors, restless leg syndrome or other related movement disorders

  Contraindications
  Hypersensitivity to the active substance or to any of the excipients